亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

One-step 3D Differentiation of Cardiac Cells from Adult Human iPS Cells

詳細技術說明
Current state-of-the-art human iPS cell differentiation into contracting cardiomyocytes (CMs)follows either a 2D sheet approach or employs 3D cell aggregates (embryoid bodies). Both ofthese techniques require cells to be dissociated for downstream applications, including formationof engineered heart tissues and potential clinical applications, resulting in multiple cell handlingsteps and high levels of cell death. This method cultures and differentiates human iPS cells intocardiomyocytes directly in PEG-fibrinogen, a biodegradable hybrid biomaterial. 2D culturing ordifferentiating prior to 3D hydrogel formation is not required. Cardiomyocytes generated by thismethod retain their contractile function at ~140 beats/minute for several months and haveobservable aligned sarcomeres, Z-bands, H-bands, and t-tubules. Sarcomeric α-actinin, Cx43,and Nkx2.5 have been detected throughout the entire tissue (Panels c & d below). This methodcan be used for more rapid, cost effective production of 3D cardiomyocyte structures for drugscreening, engineered cardiac tissue formation, or other uses.
*Abstract

Engineered cardiac tissues can be useful in medical applications, drug screens, and research. Inthe U.S. alone, the regenerative cardiac tissue market is expected to top $20 billion by 2019.Generating cardiac tissue from induced pluripotent stem cells (iPS cells) provides the ability tostudy human cardiac physiology and drug responses in culture, and the potential to createcardiac cells for clinical therapies. These cardiac tissues also avoid ethical concerns involving theuse of embryonic stem cells. However, tools and reagents for working with these cells areexpensive and culturing can be time-consuming. A faster method for growing and differentiatinghuman iPS cells directly in a 3D environment has been devised that saves both time and moneywhile generating high quality, mature cardiac tissue.

Advantages include:

(1) Faster and less expensive than existing methods

(2) Differentiates directly in 3D, reducing cell handling and increasing cell survival by up to 2X

(3) Allows formation of mature cardiac structures not observed using other approaches

(4) 3D geometries are flexible and compatible as printable hydrogels

(5) Human iPSCs can be used — no embryonic stem cells are needed

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備